Techniques to Optimize the Use of Optical Coherence Tomography: Insights from the Manufacturer and User Facility Device Experience (MAUDE) Database.


Journal

Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551

Informations de publication

Date de publication:
06 2019
Historique:
received: 12 03 2019
accepted: 12 03 2019
pubmed: 10 4 2019
medline: 17 6 2020
entrez: 10 4 2019
Statut: ppublish

Résumé

Optical coherence tomography (OCT) is a high-resolution intravascular imaging modality used to assess coronary arteries and as an adjunctive tool for optimization of percutaneous coronary interventions. Overall, the rate of complications and adverse events related to intravascular imaging is low. Limited data exist on the most commonly reported complications and modes of failure related to the use of OCT. Therefore, we analyzed the post-marketing surveillance data from the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) database to assess the reported complications and failure modes for OCT and reviewed techniques to optimize device use. The MAUDE database was queried for all event reports involving coronary OCT devices. Two independent reviewers identified 49 device reports included in the final analysis. Modes of failure and device-related patient complications were assessed. Of the 49 cases with reported device-related issues, 6.1% involved malfunction prior to insertion of the OCT catheter, and 30.6% of reported events did not result in an associated patient-related adverse event. The most commonly reported adverse events included coronary dissection and difficulty removing the catheter within a previously stented segment. No events of contrast-induced nephropathy were reported. Findings from the MAUDE database highlight the modes of device-related events associated with OCT. Device issues are uncommon, and as a result, users should be aware of optimal techniques to prevent and minimize adverse events related to device use.

Sections du résumé

BACKGROUND/PURPOSE
Optical coherence tomography (OCT) is a high-resolution intravascular imaging modality used to assess coronary arteries and as an adjunctive tool for optimization of percutaneous coronary interventions. Overall, the rate of complications and adverse events related to intravascular imaging is low. Limited data exist on the most commonly reported complications and modes of failure related to the use of OCT. Therefore, we analyzed the post-marketing surveillance data from the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) database to assess the reported complications and failure modes for OCT and reviewed techniques to optimize device use.
METHODS/MATERIALS
The MAUDE database was queried for all event reports involving coronary OCT devices. Two independent reviewers identified 49 device reports included in the final analysis. Modes of failure and device-related patient complications were assessed.
RESULTS
Of the 49 cases with reported device-related issues, 6.1% involved malfunction prior to insertion of the OCT catheter, and 30.6% of reported events did not result in an associated patient-related adverse event. The most commonly reported adverse events included coronary dissection and difficulty removing the catheter within a previously stented segment. No events of contrast-induced nephropathy were reported.
CONCLUSIONS
Findings from the MAUDE database highlight the modes of device-related events associated with OCT. Device issues are uncommon, and as a result, users should be aware of optimal techniques to prevent and minimize adverse events related to device use.

Identifiants

pubmed: 30962083
pii: S1553-8389(19)30171-X
doi: 10.1016/j.carrev.2019.03.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

507-512

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Evan Shlofmitz (E)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, United States of America.

Hector M Garcia-Garcia (HM)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, United States of America.

Toby Rogers (T)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, United States of America; Cardiovascular and Pulmonary Branch, Division of Intramural Research, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, United States of America.

Nauman Khalid (N)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, United States of America.

Yuefeng Chen (Y)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, United States of America.

Alexandre H Kajita (AH)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, United States of America.

Jaffar M Khan (JM)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, United States of America; Cardiovascular and Pulmonary Branch, Division of Intramural Research, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, United States of America.

Micaela Iantorno (M)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, United States of America.

Robert A Gallino (RA)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, United States of America.

Nelson L Bernardo (NL)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, United States of America.

Hayder Hashim (H)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, United States of America.

Rebecca Torguson (R)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, United States of America.

Ron Waksman (R)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, United States of America. Electronic address: ron.waksman@medstar.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH